If Viking Therapeutics Is Acquired, Here’s Who Wins

Polymarket traders are watching 1 biotech much intimately than immoderate different for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired earlier 2027, with all-time measurement supra $1.68 cardinal connected that azygous contract. The hook is obesity. Viking's VK2735 dual GLP-1/GIP agonist is arguably the astir precocious obesity plus not yet owned by Big Pharma. This script investigation examines who would really payment if a woody happens.

Why Viking Is the Most-Watched M&A Target

Viking is simply a clinical-stage biotech with nary gross and a marketplace headdress adjacent $3.59 billion. Shares closed astatine $30.89 connected May 22, 2026, down 12.2% twelvemonth to date. Analyst sentiment, however, is striking, with astir each analysts standing it Buy oregon Strong Buy, and a mean people terms each the mode up astatine $92.33.

The pb plus is doing the talking. Oral VK2735 delivered up to 12.2% value nonaccomplishment astatine 13 weeks, with 80% of participants achieving astatine slightest 10% value loss. Phase 3 VANQUISH-1 is afloat enrolled with 4,500+ patients. Cash pain is accelerating: Q4 2025 nett nonaccomplishment deed $157.66 cardinal against astir $706 cardinal successful cash, sharpening the strategical clock.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Viking Therapeutics wasn't 1 of them. Get them present FREE.

Existing Shareholders Benefit

For existent holders, the standalone lawsuit is the $92.33 expert target, which assumes palmy Phase 3 readouts. A woody would compress that timeline. Biotech buyouts of clinical-stage assets person historically closed good supra prevailing prices, and caller obesity deals (notably Pfizer's astir $9.8 cardinal Metsera acquisition) acceptable a notation point. Speculative buyout investing remains 1 of the highest-risk strategies successful biotech: proceedings setbacks, regulatory delays, and woody breaks tin each deed hard.

The Potential Buyer Benefits

Eli Lilly (NYSE: LLY) already dominates the category. Q1 2026 gross of astir $19.8 cardinal grew 55.5%, with Mounjaro and Zepbound leading. A 2nd level inactive adds optionality, though antitrust optics complicate the acceptable astatine its $949.7 cardinal marketplace cap.

Pfizer (NYSE: PFE) has been the astir progressive acquirer successful obesity. CEO Albert Bourla said, "2026 volition beryllium an important twelvemonth affluent successful cardinal catalysts, including our anticipation for astir 20 cardinal pivotal survey starts." A Phase 3-ready dual agonist would integrate straight into the Metsera pipeline buildout.